PGP and cancer: Clinical trials using increasingly more potent and specific inhibitors of P-gp drug efflux function (1st to 3rd generation MDR-reversing drugs) have been largely unsuccessful due to unacceptable toxicity, when combined with cytotoxic anti-cancer drugs, likely due to altered drug pharmaco-kinetics [9, 10].